Get the Stockscreener App
29.41
3.23%
0.92
After Hours:
29.41
Spyre Therapeutics Inc stock is traded at $29.41, with a volume of 375.62K.
It is up +3.23% in the last 24 hours and up +2.30% over the past month.
See More
Previous Close:
$28.49
Open:
$28.39
24h Volume:
375.62K
Relative Volume:
0.62
Market Cap:
$1.58B
Revenue:
$1.23M
Net Income/Loss:
$-364.23M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-110.82M
1W Performance:
-1.57%
1M Performance:
+2.30%
6M Performance:
-22.46%
1Y Performance:
+0.00%
1-Day Range:
$28.39
$29.94
1-Week Range:
$27.64
$30.52
52-Week Range:
$10.42
$47.97
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics Inc
Sector
Industry
Phone
(617) 651-5940
Address
221 CRESCENT STREET, WALTHAM
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Dec-11-23 | Initiated | Guggenheim | Buy |
| Dec-11-23 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| Mar-21-19 | Initiated | JP Morgan | Overweight |
| Sep-04-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Apr-24-18 | Initiated | Evercore ISI | Outperform |
| Mar-14-18 | Reiterated | Needham | Buy |
View All
Spyre Therapeutics Inc Stock (SYRE) Latest News
Market Watch: Spyre Therapeutics Inc. (SYRE)’s Noteworthy Drop, Closing at 28.49 - The Dwinnex
There is no way Spyre Therapeutics Inc. (SYRE) can keep these numbers up - SETE News
Recent Insider Activity Suggests Potential Gains for Spyre Therapeutics Inc. (SYRE) - Knox Daily
Perceptive Advisors LLC Increases Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
687,080 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Bought by Driehaus Capital Management LLC - MarketBeat
Ensign Peak Advisors Inc Invests $1.94 Million in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Armistice Capital LLC Invests $3.20 Million in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
452,040 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Darwin Global Management Ltd. - MarketBeat
Affinity Asset Advisors LLC Purchases New Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 4.1% - Defense World
575,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Bought by Logos Global Management LP - Defense World
Ratios Uncovered: Breaking Down Spyre Therapeutics Inc. (SYRE)’s Trailing Twelve Months Metrics - The Dwinnex
Spyre Therapeutics Inc.’s results are impressive - US Post News
Great Point Partners LLC Purchases Shares of 134,612 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Integral Health Asset Management LLC Buys New Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLC - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - MarketBeat
Avoro Capital Advisors LLC Purchases Shares of 1,839,138 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Rhumbline Advisers Purchases Shares of 51,896 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Trading 4.3% Higher - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 4.3% - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of "Buy" from Analysts - MarketBeat
Spruce Biosciences Inc’s results are impressive - US Post News
SciSparc advances phase IIb trial for Tourette Syndrome treatment By Investing.com - Investing.com Australia
Financial Fitness Check: Examining Spruce Biosciences Inc (SPRB)’s Key Ratios - The Dwinnex
Spyre Therapeutics (NASDAQ:SYRE) Trading Down 5% - Defense World
Is Spyre Therapeutics Inc. (SYRE) positioned for future growth? - SETE News
SciSparc Ltd [SPRC] is -94.10% lower this YTD. Is it still time to buy? - The DBT News
SciSparc Ltd Inc. (SPRC) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Do investors need to be concerned about Spyre Therapeutics Inc. (SYRE)? - US Post News
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5% - MarketBeat
Bank of New York Mellon Corp Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Daily Market Movement: Spyre Therapeutics Inc. (SYRE) Sees a 3.23 Increase, Closing at 29.36 - The Dwinnex
TD Asset Management Inc Takes $827,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
First Turn Management LLC Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics to Participate in Upcoming Investor Conference - StockTitan
Candriam S.C.A. Buys Shares of 105,000 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 4.5% - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Forecasted to Earn Q3 2024 Earnings of ($0.45) Per Share - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 4.5% - MarketBeat
Spyre Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.45) Per Share, Wedbush Forecasts (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Now Covered by Analysts at Wedbush - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up to $26.60 - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Coverage Initiated at Wedbush - MarketBeat
Spyre Therapeutics Inc. (SYRE) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 2.4% - MarketBeat
A stock that deserves closer examination: Spyre Therapeutics Inc. (SYRE) - US Post News
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):